Related Experiment Video
Updated: Jun 4, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Proteomic insights into chronic anthracycline cardiotoxicity
Martin Stěrba1, Olga Popelová, Juraj Lenčo
1Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic. sterbam@lfhk.cuni.cz
Abstract:
Chronic anthracycline cardiotoxicity is a feared complication of cancer chemotherapy. However, despite several decades of primarily hypothesis-driven research, the molecular basis of this phenomenon remains poorly understood. The aim of this study was to obtain integrative molecular insights into chronic anthracycline cardiotoxicity and the resulting heart failure. Cardiotoxicity was induced in rabbits (daunorubicin 3mg/kg, weekly, 10weeks) and changes in the left ventricular proteome were analyzed by 2D-DIGE. The protein spots with significant changes (p<0.01, >1.5-fold) were identified using MALDI-TOF/TOF. Key data were corroborated by immunohistochemistry, qRT-PCR and enzyme activity determination and compared with functional, morphological and biochemical data. The most important alterations were found in mitochondria - especially in proteins crucial for oxidative phosphorylation, energy channeling, antioxidant defense and mitochondrial stress. Furthermore, the intermediate filament desmin, which interacts with mitochondria, was determined to be distinctly up-regulated and disorganized in its expression pattern. Interestingly, the latter changes reflected the intensity of toxic damage in whole hearts as well as in individual cells. In addition, a marked drop in myosin light chain isoforms, activation of proteolytic machinery (including the proteasome system), increased abundance of chaperones and proteins involved in chaperone-mediated autophagy, membrane repair as well as apoptosis were found. In addition, dramatic changes in proteins of basement membrane and extracellular matrix were documented. In conclusion, for the first time, the complex proteomic signature of chronic anthracycline cardiotoxicity was revealed which enhances our understanding of the basis for this phenomenon and it may enhance efforts in targeting its reduction.
Insights
Chronic anthracycline cardiotoxicity, a chemotherapy side effect, damages heart mitochondria and proteins. This study reveals key molecular changes, offering insights for reducing heart failure risk.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- Chronic anthracycline cardiotoxicity is a serious, poorly understood complication of cancer chemotherapy.
- Decades of research have not fully elucidated the molecular mechanisms underlying this heart failure.
- Understanding these mechanisms is crucial for developing preventative or therapeutic strategies.
Purpose of the Study:
- To gain integrative molecular insights into chronic anthracycline cardiotoxicity using a proteomic approach.
- To identify key molecular alterations in the heart following anthracycline treatment.
- To correlate proteomic changes with functional and morphological data.
Main Methods:
- Anthracycline cardiotoxicity induced in rabbits using daunorubicin.
- Left ventricular proteome analyzed via 2D-DIGE and MALDI-TOF/TOF.
- Key findings validated by immunohistochemistry, qRT-PCR, and enzyme activity assays.
Main Results:
- Significant alterations identified in mitochondrial proteins involved in oxidative phosphorylation, energy metabolism, and antioxidant defense.
- Up-regulation and disorganization of the intermediate filament desmin, correlating with toxic damage.
- Changes observed in myosin light chains, proteolytic machinery, chaperones, autophagy proteins, and extracellular matrix components.
Conclusions:
- The study presents the first comprehensive proteomic signature of chronic anthracycline cardiotoxicity.
- Identified molecular changes provide a deeper understanding of the basis of chemotherapy-induced heart failure.
- Findings may facilitate the development of targeted interventions to mitigate cardiotoxicity.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification

